Cardiax 100% owned subsidiary ATCOR has Regulatory cleared SphygmoCor Technology considered to be the gold standard in the non-invasive central blood pressure waveform measurement which has gained a strong foothold in clinical research setting in US.
- Current Medical Devices Value Proposition in Numbers
- Its currently used in 6 continents, 34 countries, 4000 plus installations
- Over 1000 peer reviewed studies
- 14 Patents covering significant applications in cardiovascular health and consumer wearables
- 16 New Trademarks
- FDA and CFDA Approved
- Already obtained US reimbursement CPT Code
- All “Top 20 Hospitals” use SphygmoCor® technology to measure central blood pressure (cBP)
- 1,400+ studies using the SphygmoCor® technology have been published in peer-reviewed clinical publication
- 8 out of Top 10 Pharma companies have used SphygmoCor® technology in their clinical trials
- Over 11,000 patients have been tested with SphygmoCor® technology in pharmaceutical trials
Below is the screenshot of the slide from recent Presso.
Company is developing multiple new products and revenue streams from 5 new devices, 3 Partnerships and 3 Digital..... Not in 3 or 5 or 7 years.... All happening in 2020 and 2021
Focused on largest health technology markets
Medical/ Home-Use: Market opportunity of US $2.5 Billion by 2025
Consumer Wearables: Market opportunity of US $37 Billion by 2025
Arty Digital Hub-IoMT: Market opportunity of US $509 Billion by 2025
Good luck to all. Please do your own research.
Add to My Watchlist
What is My Watchlist?
